December 2005
Worldwide Biotech;Dec2005, Vol. 17 Issue 12, p3
Trade Publication
Reports on a collaborative agreement signed between Biolex Therapeutics and Kringle Pharma Inc., under which Biolex will use its LEX System for protein expression to develop a commercial line for Kringle's NK4 protein. Information on NK4; Background of the companies.


Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;4/25/2008, Vol. 19 Issue 81, p2 

    This section offers news briefs on the pharmaceutical industry in the U.S. Addex Pharmaceuticals has started Phase I testing of two formulations of ADX10059, a negative allosteric modulator that targets mGluR5. Positive results were presented by Biolex Therapeutics Inc. from its SELECT-1 phase...

  • BIOLEX OFFERS ENHANCED PRODUCT DEVELOPMENT. Salgado, Drian // Manufacturing Today;May/Jun2006, Vol. 6 Issue 3, p66 

    The article states that biopharmaceutical industry Biolex Therapeutic offers enhanced product development. The LEX system developed by the firm is capable of taking a therapeutic protein all the way from amino acid sequence through scale-up of purified content good manufacturing process...

  • OTHER NEWS TO NOTE.  // BioWorld Today;2/20/2008, Vol. 19 Issue 34, p2 

    This section offers news briefs related to the biopharmaceutical sector. Milestone payment was received by Ablynx NV from Novartis AG for an exclusive research license under an ongoing research and development collaboration to discover and develop therapeutic Nanobodies. A collaboration...

  • Pharma facility finalists announced.  // R&D Magazine;Feb2006, Vol. 48 Issue 2, p21 

    The article reports on the decision of the officials from the 27th Interphex Conference and Exhibition to announce the pharmaceutical manufacturing sites finalists for its second annual Facility of the Year Award. Among the 2006 finalists includes AstraZeneca for its large scale laboratory...

  • Controlled release drug delivery system.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p40 

    The article reports that Dutch drug delivery and development firm, OctoPlus, has been successful in the clinical trials it has conducted with partner Biolex Therapeutics. The two companies are trying to develop a controlled release treatment for hepatitis C by applying OctoPlus' PolyActive...

  • REGIONAL REPORT: Triangle.  // Business North Carolina;Dec2008, Vol. 28 Issue 12, p24 

    This section offers news briefs related to business in North Carolina. Employment at the Research Triangle Park (RTP) near Durham has reached 42,000. Amkor Technologies plans to close its semiconductor factory in Morrisville by July 2009. Biolex Therapeutics has raised $60 million in a funding...

  • Financings Roundup.  // BioWorld Today;7/14/2008, Vol. 19 Issue 135, p10 

    This article reports that OctoPlus NV of the Netherlands will receive an additional €2 million under the terms of its bridge financing that started in March 2008. The said payment was made by Biolex Therapeutics Inc., the company's co-development partner in Locerton. This amount will allow...

  • Locteron Developer Biolex Liquidates; $35M in the Red. Shaffer, Catherine // BioWorld Today;7/11/2012, Vol. 23 Issue 133, p1 

    The article details the announcement made by OctoPlus N.V., provider of pharmaceutical services, that its partner Biolex Therapeutics Inc., has already filed bankruptcy liquidation. Biolex filed a voluntary petition for liquidation under Chapter 7 in the Bankruptcy Court for the Middle District...

  • CLINIC ROUNDUP.  // BioWorld Today;3/17/2010, Vol. 21 Issue 51, p7 

    This section offers news briefs on clinical trials including the positive results obtained by Biolex Therapeutics Inc. from its Phase IIb study of a controlled-released formulation of interferon alpha and enrollment of the first patient in Nuvo Research Incorporated's European Phase II trial of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics